Lead sponsor
Voyager Pharmaceutical Corporation
3 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
3
Trials led
0
Ongoing
735
Total enrollment
67
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
2
Phase 3
1
Trials by status
Completed
3
Trials led
TrialEligibility highlightPhaseStatusEnrollment
ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)mild-to-moderate ADPh 3Completed555
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 StudyAlzheimer's diseasePh 2Completed90
ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigationAlzheimer's diseasePh 2Completed90